VCBeat's 2025 Chinese high-end ophthalmic report: 122 approvals with domestic outnumbering imports in key segments

A strategic shift is underway in China's high-end ophthalmic market. By May 2025, the NMPA had approved 122 high-end ophthalmic products, with domestic models now leading in key segments like OCT and optical biometers.

VCBeat's 2025 Chinese High-End Ophthalmic Report delves into this transformation and the determined strides of Chinese innovators like TowardPi and Moptim.